

Assessment of Therapeutic Bio-Activity of Cinnamoyl Sulfonamide Hydroxamate in Squamous Cell Carcinoma

Review began 08/10/2023
Review ended 08/15/2023
Published 08/22/2023

© Copyright 2023

Cherian et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Eapen Cherian ¹, Manoj Goyal ², Neeti Mittal ³, Venu Yesodharan ⁴, Ramya Ramadoss ⁵, Cinu Thomas ⁶

1. Oral Pathology and Oral Biology, Travancore Dental College, Kollam, IND 2. Oral & Maxillofacial Surgery, Santosh Deemed to be University, Ghaziabad, IND 3. Pediatric Dentistry, Santosh Deemed to be University, Ghaziabad, IND 4. Oral and Maxillofacial Surgery, Travancore Dental College, Kollam, IND 5. Oral Biology, Saveetha Dental College, Chennai, IND 6. Pharmacy, Caritas College of Pharmacy, Kottayam, IND

Corresponding author: Ramya Ramadoss, drramya268@gmail.com

Abstract

Background

Cancer is the second most common cause of death. Oral squamous cell carcinoma (OSCC) represents the most frequent of all oral neoplasms. Many treatment modalities such as chemotherapy, radiotherapy, surgery, and immunotherapy are emerging but still, the patients' quality of life is questionable. Despite the advances in therapeutic approaches, the percentages of morbidity and mortality of OSCC have not improved significantly during the last 30 years. Treatment using natural products can act as a potent anti-cancer agent with reduced adverse effects. Cinnamic acid derivatives exhibit anti-cancer potential through histone deacetylase inhibitor (HDAC) enzyme inhibition.

Methodology

In an experimental study design, cinnamoyl hydroxamate derivatives were prepared. The structure was confirmed using ultraviolet-visible spectroscopy (UV-Vis), nuclear magnetic resonance (NMR), infrared spectroscopy, and mass spectrophotometry. An in-vitro antioxidant assay using nitric oxide scavenging and reducing power assay was done and an in-vitro cytotoxic (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) (MTT) assay and viability assay were carried out using trypan blue dye.

Results

Statistical analysis was performed using SPSS (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp). Cinnamoyl hydroxamate derivatives were obtained and named as compounds 3a (E)-N-Hydroxy-3-(4-(N-(phenyl bromo) sulfamoyl) phenyl) acrylamide-) and 3b ((E)-N-Hydroxy-3-(4-(N-(phenyl nitro) sulfamoyl) phenyl) acrylamide). In the nitric oxide scavenging assay, compound 3a showed good antioxidant activity than 3b. Reducing power assay was higher in 3a compared to 3b. Cell viability using trypan blue exhibited a concentration decrease in % cell viability with an increase in the concentration of human oral cavity squamous cell carcinoma cell line (OECM 1), a unique head and neck squamous carcinoma cell line (UM SCC 6) & human oral squamous cell carcinoma forming metastatic foci (HSC 3) cell lines.

Conclusion

The results of the present study revealed that the study compounds play a vital role in the up-regulation of apoptotic pathways and regulation of terminal differentiation pathways. The compounds showed good anti-oxidant and anti-cancer activities in lesser concentrations, hence they can be used as a therapeutic agent for oral squamous cell carcinoma.

Categories: Genetics, Oncology, Dentistry

Keywords: bio activity, anti-cancer, mtt assay, oral squamous cell carcinoma, cinnamoyl sulfonamide, cinnamon, cancer

Introduction

The major global cause of adult mortality is cancer. The term "oral cancer" refers to a diverse range of cancers that can develop in the mouth in various locations. More than 4.5 million people worldwide pass away from cancer each year, with an estimated nine million new cases being diagnosed each year. Oral cancer is one of the top three types of cancer in India, accounting for the second and third most prevalent types of cancer in men and women, respectively [1].

Uncertainty, exposure to harsh climatic conditions, and behavioral risk factors are signs of a broad range of incidences over the world. In addition to being a significant risk factor for oral cancer, periodontal diseases

How to cite this article

Cherian E, Goyal M, Mittal N, et al. (August 22, 2023) Assessment of Therapeutic Bio-Activity of Cinnamoyl Sulfonamide Hydroxamate in Squamous Cell Carcinoma. Cureus 15(8): e43949. DOI 10.7759/cureus.43949

are more common in the Indian population, where the practice of chewing paan is a major contributing factor. Inflammation, which is brought on by bacterial and viral infections as well as inflammation, is involved in the development of tumors [1].

Oral squamous cell carcinogenesis is a multi-step process in which several genetic occurrences modify the oncogenes' and tumor suppressor genes' typical roles, disrupting the pathways normally used for regulatory control. This may lead to a rise in the production of transcription factors, growth factors, or the number of cell surface receptors, as well as improved intracellular messenger signaling. This causes a cell phenotype capable of enhanced cell proliferation, with a lack of cell cohesion, and the ability to infiltrate local tissue and spread to distant areas when combined with the loss of tumor suppressor activity [2].

Conventional diagnostic techniques like clinical and histopathological examination, vital staining, biopsy, and spectroscopic analysis are been used to detect oral cancer. But diagnosing cancer at an early stage will help in better survival and quality of life of the patients.

Based on the staging of the cancer, the treatment modalities vary. Chemotherapy, radiotherapy, surgery, targeted therapy, and immune therapy are the various treatment for treating oral cancer. Each therapy has its pros and cons. Oral cancer patients undergo various physical and psychological adverse effects which can be short-term or long-term. Cancer survivors face many ill effects like recurrence or secondary tumors along with cardiovascular, renal, and lung complications. The OSCC patients treated with surgery usually have difficulties in swallowing and speech, and also treatment can lead to neuralgia, altered or complete loss of taste sensation. Surgery can also cause cosmetic disfigurement which may require further reconstruction and rehabilitation [3].

Various Indian herbs have been used as anti-cancer agents are *Curcuma longa*, *Zingiber officinale*, *Cinnamomum verum*, *Crocus sativus*, *Ocimum sanctum*, *Azadirachta indica*, and so on. A vital substance present in plants like *Cinnamomum cassia* (Chinese cinnamon) and *Panax ginseng* is cinnamic acid, a naturally occurring aromatic carboxylic acid. Cinnamon bark is used to make cinnamic acid. Its structure, which consists of a benzene ring, an alkene double bond, and a functional group of acrylic acid, allows for the modification of the aforementioned functionalities with a wide range of substances to produce bioactive molecules with increased efficacy. It has been discovered that the type of substituents added to cinnamic acid has a significant impact on how biologically effective are synthesized cinnamic acid derivatives [4].

Cinnamic acid possesses anti-cancer, anti-diabetic, anti-inflammatory, anti-bacterial, and neuroprotective effects. By giving the electrons that interact with radicals to produce stable products, cinnamic acid stops the radical chain reactions. Detergents, flavorings, cosmetics, and toiletries all use it as a fragrant element. Enzymatic deamination of phenylalanine can produce cinnamic acid. Derivatives of cinnamic acid have anti-cancer properties and are effective against a variety of malignancies, including breast, colon, and lung cancers. It has been noted that cinnamic compounds have anti-proliferative effects on tumors. Apoptosis is one method used by cinnamic acid derivatives, such as cinnamaldehyde, to kill malignant cells [5].

Through the suppression of the histone deacetylase inhibitor (HDAC enzyme), derivatives of cinnamoyl sulfonamide hydroxamate show selective anti-cancer action in human cancer cells. HDAC inhibitors target microtubules and impair the control of mitotic progression, induce apoptosis, and thus are potent anti-cancer agents. Thus the present study will evaluate the anti-cancer activity of cinnamoyl sulfonamide hydroxamate derivatives against squamous cell carcinoma.

Materials And Methods

The present study is an experimental research, carried out in Santosh Dental College. The material preparation and analysis are carried out in Caritas College of Pharmacy, Kottayam, and the cell culture techniques are carried out in Biogenics, Trivandrum. The study was carried out in various phases. The ethical clearance was obtained with reference 856/PO/Re/S/04/CPSEA.

Design of cinnamoyl hydroxamate derivatives

(E)-3-(4-(Chlorosulfamoyl) Phenyl) Acrylic Acid Synthesis

Chlorosulfonic acid (0.69g at 5.4 mM) and cinnamic acid (1.0 g, at 0.0068 mM) were mixed at 35 °C for four hours. To keep an eye on the reaction's development, pre-coated thin-layer chromatography (TLC) plates were employed. A beaker containing ice cubes was then filled with the viscous reaction mixture. The resulting yellow precipitate (anhydrous CaCl₂) was filtered and it was washed thrice with 20 ml of distilled water and dried in a vacuum to reduce free anhydrous molecules.

(E)-3-(4-(N-(Phenyl Bromo) or (Phenyl Nitro) Sulfamoyl) Phenyl) Acrylic Acid Synthesis

Bromo aniline (0.064g, 4.06 mM) or nitro aniline (0.056, 4.06 mM) were added to a quantity of (E)-3-(4-(chlorosulfamoyl) phenyl) acrylic acid (1 g, 4.06 mM) in 50 ml distilled water, and pH 8 was maintained

using aqueous NaHCO₃. At 35° C, the reaction mixture was agitated for four hours. The liquid was then adjusted to have a pH of 2 by adding hydrogen chloride (HCl) drop by drop. Product three was recovered as a white precipitate after being washed repeatedly with water, dried, and then ethyl acetate is used to recrystallize.

(E)-N-Hydroxy-3-(4-(N-(Phenyl Bromo) or (Phenyl Nitro) Sulfamoyl) Phenyl) Acrylamide Synthesis

Using a calcium chloride guard tube, compound (E)-N-Hydroxy-3-(4-(N-(phenyl bromo) (1.5 g, 39.26 mM) was added to 30 ml of dichloromethane (Cl₂CH₂), along with ethyl chloroformate (5.10 g, 47.12 mM) and N-methyl-morpholine (3.9 g, 39.26 mM). The reaction mixture was then agitated at 35 °C for five hours. On a pre-coated TLC plate, the full translation of acrylic acid to acid chloride was seen. Additionally, the addition of freshly made neutral hydroxylamine solution (1.96 g, 58.89 mM) in 30 ml of tetra-hydro-furan (THF) completed the translation of acid chloride to the corresponding hydroxamate derivative. To create the finished product, column chromatography was used to purify the recovered residue, and two compounds were retrieved (3a, 3b) was used for further analysis.

Characterization of synthesized cinnamyl sulfonamide hydroxamate derivatives

Structure Confirmation

Ultra violet visible spectroscopy (UV-Vis) was used to determine the purity of the compound and their absorbance spectrum as they absorb light at specific wavelengths with unique absorbance values. The extracted sample was analyzed using Shimadzu UV-1800 UV spectroscopy. Infrared spectroscopy (IR) was used to identify the molecular structure, identification of chemicals, their chemical bonds, and also their qualitative and quantitative determination of chemicals present. Mass spectroscopy (MS) was done to identify the unknown compounds by molecular weight determination, quantify the known compounds, and also to determine the chemical properties of the molecules present. It was done using Thermo-Fischer scientific mass spectroscopy. For nuclear magnetic resonance (NMR), a thermo-scientific pico spin spectrometer was used to identify the molecules, study the molecular interactions, and also to probe the molecular dynamics (1H and 13C).

Derivatives of synthesized cinnamyl sulfonamide hydroxamate

(E)-N-Hydroxy-3-(4-(N-(phenyl bromo) or (phenyl nitro) sulfamoyl) phenyl) acrylamide synthesis- compound 3a, 3b.

Compound 3a

(E)-N-Hydroxy-3-(4-(N-(phenyl bromo) sulfamoyl) phenyl) acrylamide- percentage yield: 2.37g, 64.56 %; molecular weight: 397g; retardation factor (R_f) value= 0.58; melting point= 184 ± 1 °C; soluble in organic solvents and insoluble in water.

Compound 3b

(E)-N-Hydroxy-3-(4-(N-(phenyl nitro) sulfamoyl) phenyl) acrylamide- percentage yield: 2.64g, 68.93 %; molecular weight: 363g; retardation factor (R_f) value= 0.86; melting point= 144 ± 1 °C; soluble in organic solvents and insoluble in water. (compound 3 was taken as it showed highly positive anti-cancer activity).

To evaluate the in-vitro antioxidant activity of derivatives

Nitric Oxide Scavenging Activity

In the nitric oxide scavenging assay, the sodium nitro prusside is kept in an aqueous solution, and will produce nitric oxide on its own, which will subsequently combine with oxygen to produce nitrite ions, which can be detected using Griess reagent. The reaction between oxygen and nitric oxide scavengers reduces the production of nitrite ions. Spectrophotometry was used to assess the nitric oxide scavenging activity. The reagents used were sodium nitroprusside, Griess reagent, and phosphate-buffered saline (PBS) reagent. Sodium nitroprusside (5 millimol L⁻¹) was mixed with various amounts of samples 3a and 3b in phosphate-buffered saline pH 7.4 before being incubated at 25°C for 30 minutes. Instead of the test drug, distilled water was used as a control in an equivalent amount. After 30 minutes of incubation, 1.5 mL of the incubated solution was removed and diluted with 1.5 mL of Griess reagent (1% sulphanilamide, 2% phosphoric acid, and 0.1% N-1-naphthyl ethylene diamine di-hydro-chloride). By measuring the absorbance of the chromophore produced after the nitrate was diazotized with sulphanilamide and then coupled with N-1 naphthyl ethylene diamine di-hydro-chloride at 546nm, the percentage scavenging activity was calculated in relation to the standard by using % inhibition = control- test/ control x 100.

Reducing Power Assay

The total anti-oxidant effect is calculated using ferric reducing antioxidant assay (FRAP). This method is predicated on the notion that the antioxidant activity grows along with the absorbance of reaction mixtures. The antioxidant compound in the samples is measured at 700 nm by a UV-spectrophotometer with potassium ferricyanide, trichloroacetic acid, and ferric chloride (nitrate with sulphanilamide and subsequent coupling with N-1 naphthyl ethylene diamine di-hydro-chloride was measured at 546 nm, and the percentage scavenging activity was measured with reference to the standard). The reagents used are potassium ferric cyanide, tricarboxylic acid cycle (TCA), ferric chloride, and PBS reagent.

Procedure: Various amounts of samples from concentration of 10mg/mL combined with 2.5ml of phosphate buffer and 2.5ml of 1% potassium ferric cyanide. After that, the mixture was heated at 50°C for 20 minutes. Instead of the test drug, distilled water was used as a control in an equivalent amount. After incubating, 2.5 ml of 10% TCA was added and kept for 10 minutes. After the upper layer (5 ml) was blended with 5 ml of distilled water and 1 ml of 0.1% ferric chloride, the absorbance was measured at 700 nm. Quercetin at 10mg/ML was used as a reference.

In-vitro viability, cytotoxicity of synthesized compounds

Viability Analysis

Trypan blue dye exclusion assay: The trypan blue dye exclusion test can be used to count the number of live cells present in a cell solution. It is predicated on the notion that live cells will have intact cell walls which block the passage of specific dyes like propidium, Trypan blue & eosin but dead cells do not. When a dye is merely introduced to a suspension of cells without first visually determining whether the cells are absorbing or rejecting the dye. Viable cells have transparent cytoplasm, while non-viable cells have blue cytoplasm. Preparation of phosphate buffered saline pH 7.4 0.19g of sodium dihydrogen phosphate (NaH₂PO₄) was mixed with 2.38g of disodium hydrogen phosphate (Na₂HPO₄) and mixed with 8g of sodium chloride and made up to 1000ml with distilled water.

Preparation of cell culture: Human oral cavity squamous cell carcinoma cell line (OECM 1) & a unique head and neck squamous carcinoma cell line (UM- SCC 6) & human oral squamous cell carcinoma forming metastatic foci (HSC-3) cell lines procured from the oral cavity of female Swiss albino mice were used in the study. After 14 days of development, multiplication, and maturation of tumor cells, 5-6 mL of oral mucous fluid was aspirated using an 18G needle and transferred to a centrifuge tube containing PBS and centrifuged for 15 minutes at 800 rpm or at a higher speed for few minutes to avoid increased dead cell count. The pellet was re-suspended in fresh PBS and the process was repeated three times, sufficiently diluted, and used for the study.

Preparation of 0.1% trypan blue dye: 10 mg trypan blue dissolved in 100 mL of normal saline. The solution was stored light in an amber color bottle at 40 C. Sample preparation 10 mg of extract was dissolved in 1mL DMSO (sample A). Step I - preparation of higher concentrations of 3a and 3b: 200µg/mL: 780µL of PBS was mixed with 20µL of sample A and 100µL cell line and 100µg/mL: 790µL of PBS was mixed with 10µL of sample A and 100µL cell line. Step II - Preparation of lower concentrations of 3a and 3b: 100µL of sample A was diluted with 900µL of DMSO (sample B) and the following lower concentrations were prepared. 20µg/mL: 780µL of PBS was mixed with 20µL of sample B and 100µL cell line. 10µg/mL: 790µL of PBS was mixed with 10µL of sample B and 100µL cell line. 5µg/mL: 795µL of PBS was mixed with 5µL of sample B and 100µL cell line. Preparation of control 900µL of PBS was mixed with 100µL cell line. The cell suspension was contained in the control tube. They were mixed and incubated for three hours at 37°C and 0.1ml of the assay mixture was mixed with 0.1ml of trypan blue dye and then the percent of non-viable cells was evaluated. The cells were counted using a hemocytometer. The percentage of viability was calculated by dividing the number of viable cells by the total number of cells and multiple by 100.

Analysis of cytotoxicity

MTT Assay

The MTT assay was carried out using OECM 1, UM-SCC 6 & HSC 3 cell lines. The various reagents used are MTT reagent, dimethyl sulfoxide (DMSO), and Dulbecco's modified eagle medium (DMEM). The OECM 1 and UM- SCC 6 and HSC 3 cells were cultured in DMEM. Cell lines were grown in a 25 cm² tissue culture flask with an antibiotic solution containing amphotericin, penicillin, and streptomycin as well as DMEM supplemented with 10% FBS, L-glutamine, and sodium bicarbonate. Cultured cell lines were maintained at 37°C in an incubator with humidified 5% CO₂. Through direct observation of the cells using an inverted phase contrast microscope and the MTT assay method, the vitality of the cells was assessed.

Materials required: OECM 1, UM- SCC 6 & HSC 3 Cell lines, MTT reagent, DMSO, DMEM medium.

Procedure: Seeding of cells in a 96-well plate trypsinized two-day-old confluent monolayer of cells was sown in 96-well tissue culture plates at a density of 5 x 10⁴ cells per well. The cells were then incubated at 37 °C on a humidified 5% CO₂ incubator.

Compound stock preparation: Using a cyclomixer, 1mg of each of the test substances 3a and 3b were weighed and dissolved in 1mL DMEM. To guarantee sterility, a 0.22 m Millipore syringe filter was used to filter the sample solution. After 24 hours, the growth media was withdrawn for the anticancer evaluation. Five freshly produced compounds in 5% DMEM were serially diluted two folds five times (100g, 50g, 25g, 12.5g, and 6.25g in 500l of 5% DMEM). After receiving treatment for 24 hours, the complete plate was examined under an inverted phase contrast tissue culture microscope for an anticancer assay, and microscopic observations were captured as photographs. Cellular morphological alterations like rounding or shrinkage, granulation, and vacuolization in the cytoplasm were all taken into account as indications of cytotoxicity.

Results

Statistical analysis was performed using SSPSS (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp). A chi-square test was carried out to check for any statistical difference between the observed value and the expected value among the control and study group. One-way ANOVA analysis was carried out to compare the means and determine the association between the means of the study group. Post-hoc Tukey HSD (beta) was performed to facilitate pairwise comparisons within the analysis of variance (ANOVA) data. The level of significance [P-Value] was set at $P < 0.05$.

Cinnamyl sulfonamide hydroxamate derivatives

Compound 3a

(E)-N-Hydroxy-3-(4-(N-(phenyl bromo) sulfamoyl) phenyl) acrylamide- percentage yield: 2.37g, 64.56 %; molecular weight: 397g; retardation factor (Rf) value= 0.58; melting point= 184 ± 1 °C; soluble in organic solvents and insoluble in water.

Compound 3b

(E)-N-Hydroxy-3-(4-(N-(phenyl nitro) sulfamoyl) phenyl) acrylamide- percentage yield: 2.64g, 68.93 %; molecular weight: 363g; retardation factor (Rf) value= 0.86; melting point= 144 ± 1 °C; soluble in organic solvents and insoluble in water.

Structural characterization of synthesized cinnamyl sulfonamide hydroxamate derivatives

The C=O stretching was present at 1672, the C-S group was present at 672 cm^{-1} , and the presence of the O=S=O group was indicated by a peak at 1158 cm^{-1} in the FTIR spectra of the 3a. O-H and N-H groups are present, as shown by the peaks at 3260 and 2676. A peak at 3360 cm^{-1} and another at 3327 cm^{-1} in compound 3b's FTIR spectrum suggest the existence of O-H and N-H groups, respectively. Peaks for C=O at 169 cm^{-1} and for C-S at 697 cm^{-1} are also produced by the compound. The presence of the S=O group is indicated by the peak at 1179 cm^{-1} . The synthetic compounds 3a and 3b's ^1H NMR spectra reveal the existence of 10 aromatic protons in the 6-8 ppm region. Both compounds had a peak for N-H protons at 10 ppm. The synthetic compounds 3a and 3b's ^{13}C NMR spectra reveal the existence of C=O at a peak value of 167.50 and 168.11, respectively. The ranges of 124.44-142.37 and 14.36-129.12, respectively, contain the peaks in 3a and 3b showing the presence of aromatic carbons, respectively. The molecular ion peak may be seen as the base peak at m/z 398 and 365 in the mass spectra of compounds 3a and 3b. Several spectroscopic analytical techniques were used to confirm the structure of the synthesized molecules.

Nitric oxide scavenging assay

Anti-oxidant activity can be analyzed by determining the nitric oxide radical inhibition concentration carried out by 3a and 3b (two synthetic derivatives) with gallic acid as standard at reductive potential concentration (Table 1). The dose-dependent activity and % of inhibition are given as follows:

| Group | Concentration ($\mu\text{g/mL}$) | Absorbance (Mean \pm SD) | % Inhibition/ Conc |
|------------------------------|------------------------------------|----------------------------|--------------------|
| Standard Control Gallic Acid | 6.25 | 0.24 \pm 0.005 | 17.5 |
| | 12.5 | 0.19 \pm 0.004 | 34.9 |
| | 25 | 0.16 \pm 0.002 | 48.54 |
| | 50 | 0.08 \pm 0.002 | 67.08 |
| | 100 | 0.04 \pm 0.001 | 74.53 |
| | 200 | 0.02 \pm 0.001 | 95.7 |
| IC ₅₀ | 29.27 $\mu\text{g/MI}$ | | |

TABLE 1: Nitric oxide radical inhibition concentration of standard gallic acid

The percentage inhibition of the standard gallic acid increased with increasing concentration of the compound assay and showed maximum inhibition of 95.7% at 200 $\mu\text{g/mL}$ concentration and a minimum of 17.5% at 6.25 $\mu\text{g/mL}$ concentrations. Correspondingly, for both test compounds 3a and 3b, the inhibition (%) percentage scavenging increases linearly with concentration at the given cell phase. The half-maximal inhibitory concentration (IC₅₀ value for the standard gallic acid was found to be 29.27 $\mu\text{g/mL}$ whereas the IC₅₀ values of test compounds 3a and 3b were found to be 81.27 $\mu\text{g/mL}$ and 129.27 $\mu\text{g/mL}$ respectively among which 3a was found to be good antioxidant than 3b (Tables 2, 3).

| Group | Concentration ($\mu\text{g/mL}$) | Absorbance (Mean \pm SD) | % Inhibition/ Conc |
|------------------|------------------------------------|----------------------------|--------------------|
| Compound 3a | 6.25 | 0.54 \pm 0.004 | 12.5 |
| | 12.5 | 0.46 \pm 0.003 | 26.6 |
| | 25 | 0.39 \pm 0.006 | 31.4 |
| | 50 | 0.25 \pm 0.003 | 45.41 |
| | 100 | 0.18 \pm 0.001 | 63.72 |
| | 200 | 0.12 \pm 0.001 | 79.46 |
| IC ₅₀ | 81.27 $\mu\text{g/MI}$ | | |

TABLE 2: Nitric oxide radical inhibition concentration of compound 3a

| Group | Concentration ($\mu\text{g/mL}$) | Absorbance (Mean \pm SD) | % Inhibition/ Conc |
|------------------|------------------------------------|----------------------------|--------------------|
| Compound 3b | 6.25 | 0.51 \pm 0.004 | 9.5 |
| | 12.5 | 0.40 \pm 0.003 | 18.4 |
| | 25 | 0.32 \pm 0.006 | 26.74 |
| | 50 | 0.27 \pm 0.003 | 33.91 |
| | 100 | 0.19 \pm 0.001 | 46.11 |
| | 200 | 0.14 \pm 0.001 | 69.38 |
| IC ₅₀ | 129.27 $\mu\text{g/MI}$ | | |

TABLE 3: Nitric oxide radical inhibition concentration of compound 3b

Reducing power assay using standard quercetin test compound

Reducing potential was assessed by absorbance of different concentrations of compounds 3a and 3b at the given environment under standard Quercetin compound measured at 700nm (Table 4).

| Group | Concentration ($\mu\text{g/mL}$) | Absorbance (Mean \pm SD) |
|----------------------------|------------------------------------|----------------------------|
| Standard Control Quercetin | 6.25 | 0.95 \pm 0.003 |
| | 12.5 | 1.19 \pm 0.002 |
| | 25 | 1.76 \pm 0.002 |
| | 50 | 2.18 \pm 0.005 |
| | 100 | 2.64 \pm 0.006 |
| | 200 | 2.82 \pm 0.005 |

TABLE 4: Reducing power assay of the standard (quercetin)

The test compound 3a and 3b (Tables 5, 6) shows maximum absorbance (mean \pm SD) of 2.38 and 2.12 \pm 0.001 and 0.006 respectively at 200 $\mu\text{g/mL}$ and the standard control using quercetin shows maximum absorbance at the concentration of 200 $\mu\text{g/mL}$ (mean \pm SD) about 2.82 \pm 0.005. This signifies that the reducing power of compound 3a was comparatively higher than that of 3b with standard control as quercetin.

| Group | Concentration ($\mu\text{g/mL}$) | Absorbance (Mean \pm SD) |
|-------------|------------------------------------|----------------------------|
| Compound 3a | 6.25 | 0.47 \pm 0.005 |
| | 12.5 | 0.98 \pm 0.004 |
| | 25 | 1.44 \pm 0.002 |
| | 50 | 1.86 \pm 0.003 |
| | 100 | 2.07 \pm 0.006 |
| | 200 | 2.38 \pm 0.001 |

TABLE 5: Reducing power assay of the compound 3a

| Group | Concentration ($\mu\text{g/mL}$) | Absorbance (Mean \pm SD) |
|-------------|------------------------------------|----------------------------|
| Compound 3b | 6.25 | 0.42 \pm 0.001 |
| | 12.5 | 0.81 \pm 0.002 |
| | 25 | 1.27 \pm 0.002 |
| | 50 | 1.56 \pm 0.004 |
| | 100 | 2.04 \pm 0.003 |
| | 200 | 2.12 \pm 0.006 |

TABLE 6: Reducing power assay of the compound 3b

Tryphan blue

The tryphan Blue dye exclusion test can be used to count the number of sentient cells present in a given cell line suspension or solution. The OECM 1 & UM- SCC 6 & HSC-3 cell lines were cultured as per standard

procedures described earlier and stained using trypan blue to check the viability when treated with compounds 3a and 3b. In this method, dead cells appear dark blue as they take up the stain color. This stain allows the differentiation of dead cells and cells with damaged cell membranes with viable or live cells that do not take up the stain (unstained). This examines the cell suspension depending on the integrity of the cellular membrane exposed to compounds 3a and 3b in the present study with the percentage viability expressed as mean \pm SD (Tables 7, 8, 9).

| Concentration ($\mu\text{g/mL}$) | % Inhibition of cell viability of compounds | |
|------------------------------------|---|--------------------------|
| | 3a | 3b |
| 6.25 | 12.6 | 14.52 |
| 12.5 | 19.2 | 27.86 |
| 25 | 24.93 | 33.91 |
| 50 | 41.89 | 38.84 |
| 100 | 65.78 | 42.58 |
| 200 | 73.45 | 63.19 |
| LC ₅₀ | 79.637 $\mu\text{g/mL}$ | 160.051 $\mu\text{g/mL}$ |

TABLE 7: OECM-1 cell line- percentage inhibition of cell viability by compounds 3a and 3b

OECM 1: human oral cavity squamous cell carcinoma cell line

| Concentration ($\mu\text{g/mL}$) | % Inhibition of cell viability of compounds | |
|------------------------------------|---|--------------------------|
| | 3a | 3b |
| 6.25 | 11.2 | 18.34 |
| 12.5 | 19.56 | 23.48 |
| 25 | 25.4 | 29.87 |
| 50 | 39.87 | 34.79 |
| 100 | 58.36 | 41.63 |
| 200 | 66.57 | 62.49 |
| LC ₅₀ | 94.235 $\mu\text{g/mL}$ | 179.152 $\mu\text{g/mL}$ |

TABLE 8: UM-SCC 6 cell line- percentage inhibition of cell viability by compounds 3a and 3b

UM SCC 6: a unique head and neck squamous carcinoma cell line

| Concentration (µg/mL) | % Inhibition of cell viability of compounds | |
|-----------------------|---|--------------|
| | 3a | 3b |
| 6.25 | 14.35 | 15.6 |
| 12.5 | 25.65 | 21.3 |
| 25 | 38.43 | 24.27 |
| 50 | 53.26 | 39.7 |
| 100 | 69.17 | 55.48 |
| 200 | 76.31 | 63.28 |
| LC ₅₀ | 43.519 µg/mL* | 92.391 µg/mL |

TABLE 9: HSC- 3 cell line- percentage inhibition of cell viability by compounds 3a and 3b

*Highly cytotoxic; HSC 3: Human oral squamous cell carcinoma forming metastatic foci

The test compounds 3a and 3b showed a concentration-dependent decrease in percentage cell viability with an increase in concentration in OECM 1 & UM- SCC 6 & HSC-3 cell lines. The test compound 3b produces maximum percentage inhibition of viability 63.19%, 62.49%, and 63.28% at 200µg/mL respectively, and minimum inhibition of cell viability 14.52%, 18.34%, and 15.6% at 6.25µg/mL concentration. Whereas 3a showed a maximum percentage inhibition of cell viability of 73.45%, 66.57%, and 76.31% at 200µg/mL and a minimum percentage inhibition of cell viability of 12.6%, 11.2%, and 14.35% at 6.5µg/ml (Tables 7, 8, 9).

The two test compounds 3a and 3b caused significant cytotoxicity in OECM 1 & UM- SCC 6 & HSC-3 cell lines incubated with phosphate-buffered saline. The lethal concentration (LC) 50 values were found to be 79.637 µg/mL (3a) and 160.051 µg/mL (3b) for OECM-1 followed by 94.235 µg/mL (3a) and 179.152 µg/mL (3b) for UM-SCC 6 with higher toxicity at HSC-3 cell line that was found to be 43.519 µg/mL (3a) and 92.391 µg/mL (3b) lethal even at a very low concentration. Among these, the test compounds, 3a produces more cytotoxicity towards the HSC-3 cell line followed by the OECM-1 cell line and the least being 3b compound at the UM-SCC6 cell line (160.051 µg/ml at 200 µg/ml concentration).

MTT((3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay

MTT assay was carried out to evaluate the inhibition concentration and measure the viable cells by determining the mitochondrial activity after 24 hours of specified compound concentration treatment with MTT assay expressed as mean ± SD (Tables 10, 11, 12).

| Groups | Concentration (µg/ml) | Absorbance (Mean ± SD) | Percentage Inhibition (%) |
|------------------|-----------------------|------------------------|---------------------------|
| 3a | 6.25 | 2.78±0.004 | 94.5 |
| | 12.5 | 2.12±0.012 | 84.63 |
| | 25 | 1.98±0.008 | 71.56 |
| | 50 | 1.23±0.002 | 58.9 |
| | 100 | 0.87±0.013 | 41.83 |
| | 200 | 0.47±0.005 | 24.68 |
| IC ₅₀ | 78.562 µg/mL | | |
| 3b | 6.25 | 2.09±0.004 | 90.4 |
| | 12.5 | 1.93±0.012 | 82.36 |
| | 25 | 1.78±0.008 | 79.47 |
| | 50 | 1.14±0.002 | 76.12 |
| | 100 | 0.93±0.013 | 63.54 |
| | 200 | 0.42±0.005 | 47.33 |
| IC ₅₀ | 129.361 µg/mL | | |

TABLE 10: Percentage inhibition of 3a and 3b on growth of OECM 1 Cell line

OECM 1: human oral cavity squamous cell carcinoma cell line

| Groups | Concentration (µg/ml) | Absorbance (Mean ± SD) | Percentage Inhibition (%) |
|------------------|-----------------------|------------------------|---------------------------|
| 3a | 6.25 | 1.98±0.012 | 92.71 |
| | 12.5 | 1.72±0.008 | 85.4 |
| | 25 | 1.55±0.007 | 72.38 |
| | 50 | 1.29±0.011 | 63.89 |
| | 100 | 0.87±0.006 | 46.73 |
| | 200 | 0.43±0.009 | 39.56 |
| IC ₅₀ | 79.335 µg/mL | | |
| 3b | 6.25 | 2.12±0.007 | 91.9 |
| | 12.5 | 1.93±0.006 | 88.56 |
| | 25 | 1.67±0.012 | 82.37 |
| | 50 | 1.35±0.006 | 78.54 |
| | 100 | 0.93±0.007 | 59.71 |
| | 200 | 0.78±0.005 | 44.98 |
| IC ₅₀ | 157.685 µg/mL | | |

TABLE 11: Percentage inhibition of 3a and 3b on growth of UM- SCC 6 Cell line

UM SCC 6: a unique head and neck squamous carcinoma cell line

| Groups | Concentration ($\mu\text{g}/\text{mL}$) | Absorbance (Mean \pm SD) | Percentage Inhibition (%) |
|------------------|---|----------------------------|---------------------------|
| 3a | 6.25 | 2.78 \pm 0.004 | 90.23 |
| | 12.5 | 2.12 \pm 0.012 | 79.16 |
| | 25 | 1.98 \pm 0.008 | 67.12 |
| | 50 | 1.23 \pm 0.002 | 48.63 |
| | 100 | 0.87 \pm 0.013 | 41.83 |
| | 200 | 0.47 \pm 0.005 | 24.68 |
| IC ₅₀ | 46.802 $\mu\text{g}/\text{mL}$ | | |
| 3b | 6.25 | 2.78 \pm 0.004 | 89.26 |
| | 12.5 | 2.12 \pm 0.012 | 81.48 |
| | 25 | 1.98 \pm 0.008 | 72.6 |
| | 50 | 1.23 \pm 0.002 | 63.89 |
| | 100 | 0.87 \pm 0.013 | 59.17 |
| | 200 | 0.47 \pm 0.005 | 35.86 |
| IC ₅₀ | 108.521 $\mu\text{g}/\text{mL}$ | | |

TABLE 12: Percentage inhibition of 3a and 3b on growth of HSC-3 Cell line

HSC 3: Human oral squamous cell carcinoma forming metastatic foci

Discussion

Evidence-based studies showed cinnamic acid novel targeted derivatives exhibit anti-cancerous potential through HDAC inhibition by selective and less toxic molecular mechanisms. In the present study, two cinnamyl sulfonamide hydroxamate compounds (derivatives 3a, 3b) were assessed to explore the potential anti-cancerous activity of cinnamic acid derivatives. Pontiki et al. [6] observed potential anti-cancerous activity by novel synthesis method and structural configuration of cinnamic acid derivatives while a study by Reddy et al. showed 3 cinnamyl sulfonamide hydroxamate (CSH) products induces HDAC inhibition and possible activation of apoptotic pathways thus providing anti-cancerous and anti-inflammatory activity [7].

A nitrous oxide scavenging assay was performed to evaluate the percentage inhibition of the antioxidant and free radical scavenging activity. Sarwar et al. observed good antioxidant activity with IC₅₀ of 55.4 \pm 0.21 $\mu\text{g}/\text{mL}$ among *Quercus incana* roxb that increased with increasing concentration of the compound assay. Gryko et al. [8] in cinnamic acid derivatives (tHCA, dHCA) and natural cinnamic acid observed 2,2-diphenyl-1-picrylhydrazyl (DPPH), hydroxyl (HO) radicals scavenging activity and Fe³⁺ reduction ability at 10Mm (4-HCA), 0.05Mm (3, 4, 5-tHCA,dHCA) showing IC₅₀ values of 49.99 \pm 0.58, 50.22 \pm 0.55 and 53.02 \pm 0.80 with 80% of initial concentration at 100 $\mu\text{g}/\text{mL}$. In the present study, maximum inhibition of 95.7% occurred at 200 $\mu\text{g}/\text{mL}$ concentration using standard gallic acid whereas the IC₅₀ values of cinnamic derivative compounds 3a (OH derivatives) and 3b (-OH-OH derivatives) were found to be 81.27 $\mu\text{g}/\text{mL}$ and 129.27 $\mu\text{g}/\text{mL}$ respectively. Thus signifying derivatives of cinnamic acid as a potential scavenger with antiradical activity enhanced by an increased number of hydroxyl derivative groups (-OH p-hydroxy < dihydroxy < hydroxydimethyl) caused by a decrease in the kinetic stability, and influence of aromatic substitution as a result of symmetrization of the electronic charge dissemination of these 3a and 3b compound molecules [9].

Reducing potential was assessed by absorbance of different concentrations of compounds 3a and 3b at the given environment showed maximum absorbance (mean \pm SD) of 2.38 and 2.12 \pm 0.001 and 0.006 respectively at 200 $\mu\text{g}/\text{mL}$. Barre et al. in a study to evaluate the reduction potential and polypharmacy of cinnamic acid derivatives in type 2 diabetes mellitus (DM) patients observed derivatives such as chlorogenic acid, cinnamaldehyde, caffeic acid, and ferulic acid exhibited maximum reduction at lower concentrations [10]. Adisakwattana in a similar study on diabetic individuals observed the reduction potential of p-methoxy cinnamic acid at 10-100 μM concentration (11.5%) and caffeic acid (50.1%) at a slightly higher concentration [11]. Pellerito et al. showed a marked reduction at 400 nM even up to 1 μM concentration. These results suggest that the replacement of aromatic (substitute) by hydroxyl group traps the dicarbonyl's thus enhancing the reduction potential even at lower concentrations [12]. Our results also support the findings

that biochemical reactions of specific compounds play an important role in the up-regulation of apoptotic pathways and also the regulation of terminal differentiation pathways.

A trypan blue dye exclusion test was carried out to assess the number of sentinel cells present in the given OECM 1 & UM- SCC 6 & HSC-3 cell line suspension. Rodrigo et al. in a study employed cell lines derived for human oral SCC's to assess the effect of raspberry-ethanol extract (RO-ET) activity on cellular characteristics using trypan blue exclusion dye test observed cell proliferation without disorientation in the viability and cell suspension inhibition at 10, 50, and 100 µg/ml (> 97%) concentration that induces both apoptosis and differentiation [13]. Ladke et al., Chan et al. recommended the use of trypan blue for effective preservation of cell line integrity from contamination, retaining the tissue architecture, staining dead cells, viability inhibition potential, and microenvironment characterization of cell therapy. The present study showed maximum percentage inhibition of viability at 63.19%, 62.49%, and 63.28% at 200µg/mL respectively among the cinnamic derivative compounds [14, 15]. This could be attributed to concentrate gradient differentiation and membrane-compromised dead cells in the cell lines used in the present study nonetheless acceptable level of viability was observed where the appearance of live cells was not affected comparable to morphological changes for typical cancer cell cultures at high sustainability.

MTT assay was carried out to evaluate the inhibition concentration and measure the viable cells by determining the mitochondrial activity after 24 hours of specified compound concentration treatment with MTT assay expressed as mean ± SD. In a study by Jayashree et al. 2-Quinolone Schiff's bases in a novel series of constituents (15 chemicals) were produced. By using the MTT assay method, the active compounds were examined for their antiproliferative ability against lung cancer cell lines [16]. The bromo and bromo aniline derivatives were shown to be more cytotoxic among the 15 synthetic chemicals studied. Kaur et al. designed and synthesized 16 novel cinnamic acid derivatives and evaluated them for in vitro cytotoxicity (lung cancer cell line, A-549 cell culture line) using MTT assay [17]. The study showed substantial docking interactions, selective MMP-9 inhibitors as potential antineoplastic agents, and also by binding patterns with MMP-9 protein suggesting the in vitro cytotoxicity outcome nature. Mingoia et al. [18] analyzed the potential wound healing property of novel cinnamic acid derivatives using MTT assay on keratinocytes with the study compounds and revealed MTT viability assay as an effective test in evaluating the effects of derivatives in proliferation and viability at specific concentrations. Cheng et al. [19] tested the inhibitory growth potential of OECM-1 and SAS Cell lines treated with prodigiosin (PG) using MTT assay and reported a significant level of cytotoxicity with 0.4 µM of PG and 3 methyladenine (1 and 5 mM) in OECM-1 while Ardito et al. detected reduction in proliferation potential at increasing concentration and duration (24hrs, 48hrs, and 72 hrs) respectively with increasing concentration of genistein in HSC-3 cell line with an IC50 of 22µM [20].

In the present study, LC 50 values of compound (OECM 1: 3a: 79.637 µg/mL; 3b: 160.051 µg/mL) (UM-SCC 1: 3a: 94.235 µg/mL; 3b: 179.152 µg/mL) and (HSC- 3: 3a: 43.519 µg/mL; 3b: 92.391 µg/mL) for 24 hours were observed respectively thus suggesting a higher metabolic activity of compound 3a on the cell lines as an indicator of cell viability, proliferation, and cytotoxicity compared to compound 3b and high resistance potential displayed by these cell lines in response to the compounds 3a and 3b. Varadarajan et al. performed an in-vitro study to assess the anticancer property of cinnamic acid extracts using MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and observed anti-cancerous effect of 4-hydroxy-cinnamic acid and cinnamaldehyde through apoptosis by specific mitochondrial alteration in membrane potential and s-phase arrest in cell cycle [21].

Reddy et al. in an assessment of synthesized cinnamyl derivatives (NMJ-1, -2, and -3) study showed cancer cell cytotoxicity with an effective increase in the apoptotic index and arrest in the G2/M phase in the cell cycle. Induction of p21 (Waf1/Cip1) expression, hyper-acetylation of H3 histidione, inhibition of induced MMP-2, and 9 expressions. In accordance with these results the present study also on the control treatment of compounds 3a and 3b with anisidine and toluidine revealed a statistically significant difference at G0/G1 phase and S phase. A significant decrease in cells in G0/G1 phase from 70.4% to 34.0 (%Gated) and an increase in cells in the S phase from 14.8% to 38.5% (gated %) was observed suggesting S phase arrest [22].

Sova et al. demonstrated various biological effects of cinnamic acid derivatives (CAD) and cytotoxicity on HeLa, K562, Fem-x, and MCF-7 cell lines using MTT assay and showed significant cytotoxicity of the CAD compounds on the malignant cell lines [23]. Cell study analysis using flow Cytometry revealed an accumulation of cells in the G0/G1 phase followed by disruption of the cell cycle phase of viable cells in the given cell line. Similarly in the present study a marginal decrease in cells in the G0/G1 phase from 70.4% to 53.1 (%Gated) and an increase in cells in the S phase from 14.8% to 18.0% (Gated %) and at G2 M phase cells (10.9% to 14.5%) indicative of both late apoptotic and necrotic cell population when compared with untreated control cells suggesting a marginal arrest comparatively lower than anisidine at S phase.

Plants are having effective medicinal value with reduced adverse effects. Future studies on the efficacy of the drug, mode of drug release and targeted drug delivery can be carried out using animal models. The extracted study molecule can also be compared with commercial anti-cancer agents for an effective drug delivery system.

Conclusions

Exploring the targeted therapy and less harmful chemicals to treat cancer is a never-ending task. Recent rapid scientific advancements have improved our knowledge of cancer biology. As a result, a number of evolutionary targets have been found. The discovery of histone deacetylase as a new and potential target for cancer treatment. By inhibiting HDAC, cinnamic acid compounds demonstrate their anticancer effectiveness. Novel cinnamyl sulfonamide hydroxamate derivatives 3a and 3b were synthesized, characterized, and screened for their in vitro and in vivo anticancer potential. The compounds were subjected to anti-oxidant assays like ferric reducing power assay and NO scavenging assay. The test compounds 3a and 3b showed a concentration-dependent increase in the absorbance of Fe²⁺ in reducing power assay. MTT assay was carried out to evaluate the inhibition concentration and measure the viable cells, suggesting a higher metabolic activity of compound 3a on the cell lines as an indicator of cell viability, proliferation, and cytotoxicity compared to compound 3b and high resistance potential displayed by these cell lines in response to the compounds 3a and 3b.

Additional Information

Disclosures

Human subjects: All authors have confirmed that this study did not involve human participants or tissue.

Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

- Mehrotra R, Yadav S: Oral squamous cell carcinoma: etiology, pathogenesis and prognostic value of genomic alterations. *Indian J Cancer*. 2006, 43:60-6. [10.4103/0019-509x.25886](https://doi.org/10.4103/0019-509x.25886)
- Williams HK: Molecular pathogenesis of oral squamous carcinoma. *Mol Pathol*. 2000, 53:165-72. [10.1136/mp.53.4.165](https://doi.org/10.1136/mp.53.4.165)
- Gharat SA, Momin M, Bhavsar C: Oral squamous cell carcinoma: current treatment strategies and nanotechnology-based approaches for prevention and therapy. *Crit Rev Ther Drug Carrier Syst*. 2016, 33:363-400. [10.1615/CritRevTherDrugCarrierSyst.2016016272](https://doi.org/10.1615/CritRevTherDrugCarrierSyst.2016016272)
- Siddiqui AJ, Jahan S, Singh R, et al.: Plants in anticancer drug discovery: from molecular mechanism to chemoprevention. *Biomed Res Int*. 2022, 2022:5425485. [10.1155/2022/5425485](https://doi.org/10.1155/2022/5425485)
- Khedkar S, Ahmad Khan M: Aqueous extract of cinnamon (*cinnamomum spp.*): role in cancer and inflammation. *Evid Based Complement Alternat Med*. 2023, 2023:5467342. [10.1155/2023/5467342](https://doi.org/10.1155/2023/5467342)
- Pontiki E, Hadjipavlou-Litina D, Litinas K, Geromichalos G: Novel cinnamic acid derivatives as antioxidant and anticancer agents: design, synthesis and modeling studies. *Molecules*. 2014, 19:9655-74. [10.3390/molecules19079655](https://doi.org/10.3390/molecules19079655)
- Reddy ND, Shoja MH, Biswas S, Nayak PG, Kumar N, Rao CM: An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells. *Chem Biol Interact*. 2016, 253:112-24. [10.1016/j.cbi.2016.05.008](https://doi.org/10.1016/j.cbi.2016.05.008)
- Sarwar R, Farooq U, Khan A, et al.: Evaluation of antioxidant, free radical scavenging, and antimicrobial activity of quercus incana roxb. *Front Pharmacol*. 2015, 6:277. [10.3389/fphar.2015.00277](https://doi.org/10.3389/fphar.2015.00277)
- Gryko K, Kalinowska M, Ofman P, Chojińska R, Świdorski G, Świśłocka R, Lewandowski W: Natural cinnamic acid derivatives: a comprehensive study on structural, anti/pro-oxidant, and environmental impacts. *Materials (Basel)*. 2021, 14:10.3390/ma14206098
- Barre DE, Mizier-Barre KA: The polypharmacy reduction potential of cinnamic acids and some related compounds in pre- and post-onset management of type 2 diabetes mellitus. *Endocr Regul*. 2020, 54:137-55. [10.2478/enr-2020-0017](https://doi.org/10.2478/enr-2020-0017)
- Adisakwattana S: Cinnamic acid and its derivatives: mechanisms for prevention and management of diabetes and its complications. *Nutrients*. 2017, 9:10.3390/nu9020163
- Pellerito C, Emanuele S, Ferrante F, Celesia A, Giuliano M, Fiore T: Tributyltin(IV) ferulate, a novel synthetic ferulic acid derivative, induces autophagic cell death in colon cancer cells: From chemical synthesis to biochemical effects. *J Inorg Biochem*. 2020, 205:110999. [10.1016/j.jinorgbio.2020.110999](https://doi.org/10.1016/j.jinorgbio.2020.110999)
- Rodrigo KA, Rawal Y, Renner RJ, Schwartz SJ, Tian Q, Larsen PE, Mallery SR: Suppression of the tumorigenic phenotype in human oral squamous cell carcinoma cells by an ethanol extract derived from freeze-dried black raspberries. *Nutr Cancer*. 2006, 54:58-68. [10.1207/s15327914nc5401_7](https://doi.org/10.1207/s15327914nc5401_7)
- Ladke VS, Kumbhar GM, Joshi K, Kheur S, Bhonde R, Raut C: Isolation, culture and morphological assessment of primary cell lines from human primary oral squamous cell carcinoma using explant technique. *Asian Pac J Cancer Prev*. 2023, 24:257-66. [10.31557/APJCP.2023.24.1.257](https://doi.org/10.31557/APJCP.2023.24.1.257)
- Chan LL, Rice WL, Qiu J: Observation and quantification of the morphological effect of trypan blue rupturing dead or dying cells. *PLoS One*. 2020, 15:e0227950. [10.1371/journal.pone.0227950](https://doi.org/10.1371/journal.pone.0227950)
- Jayashree BS, Kaur M, Pai A: Synthesis, characterisation, antioxidant and anticancer evaluation of novel schiff's bases of 2-quinolones. *Elixir Online Journal*. 2012, 52:11317-22.
- Kaur N, Khan J, Kaleemullah M, et al.: Synthesis of cinnamic acid amide derivatives and the biological evaluation of A-glucosidase inhibitory activity. *Int J Med Toxicol Leg Med*. 2018, 21:216-20. [10.5958/0974-4614.2018.00071.2](https://doi.org/10.5958/0974-4614.2018.00071.2)
- Mingoaia M, Conte C, Di Rienzo A, et al.: Synthesis and biological evaluation of novel cinnamic acid-based antimicrobials. *Pharmaceuticals (Basel)*. 2022, 15:10.3390/ph15020228

19. Cheng MF, Lin CS, Chen YH, Sung PJ, Lin SR, Tong YW, Weng CF: Inhibitory growth of oral squamous cell carcinoma cancer via bacterial prodigiosin. *Mar Drugs*. 2017, 15: [10.3390/md15070224](https://doi.org/10.3390/md15070224)
20. Ardito F, Pellegrino MR, Perrone D, Troiano G, Cocco A, Lo Muzio L: In vitro study on anti-cancer properties of genistein in tongue cancer. *Onco Targets Ther*. 2017, 10:5405-15. [10.2147/OTT.S133632](https://doi.org/10.2147/OTT.S133632)
21. Varadarajan S, Narasimhan M, Balaji TM, Chamundeeswari DP, Sakthisekaran D: In vitro anticancer effects of cinnamomum verum j. Presl, cinnamaldehyde, 4 hydroxycinnamic acid and eugenol on an oral squamous cell carcinoma cell line. *J Contemp Dent Pract*. 2020, 21:1027-33.
22. Reddy ND, Shoja MH, Jayashree BS, et al.: In vitro and in vivo evaluation of novel cinnamyl sulfonamide hydroxamate derivative against colon adenocarcinoma. *Chem Biol Interact*. 2015, 233:81-94. [10.1016/j.cbi.2015.03.015](https://doi.org/10.1016/j.cbi.2015.03.015)
23. Sova M, Žižak Ž, Stanković JA, et al.: Cinnamic acid derivatives induce cell cycle arrest in carcinoma cell lines. *Med Chem*. 2013, 9:633-41. [10.2174/1573406411509050002](https://doi.org/10.2174/1573406411509050002)